Regional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer’s therapies
Authors
- Ursula Marschall (ORCID: https://orcid.org/0009-0008-2607-8996)
- Cordula Riederer
- Daniela Koller (ORCID: https://orcid.org/0000-0002-3203-7188)
- Daniela Gesell (ORCID: https://orcid.org/0000-0003-1930-8745)
- Michael Hauptmann (ORCID: https://orcid.org/0000-0001-8539-0148)
- Enno Swart (ORCID: https://orcid.org/0000-0002-3286-2217)
- Denise Kubat
- Dirk Horenkamp‐Sonntag
- Moritz Platen (ORCID: https://orcid.org/0000-0001-6438-7230)
- Hannah Scheibner (ORCID: https://orcid.org/0000-0002-1268-8741)
- E Glaser
- Jennifer Schroth
- Volker Dahling
- Bernhard Michalowsky
Institutions
- Universitätsmedizin Greifswald (DE)
- German Center for Neurodegenerative Diseases (DE)
- LMU Klinikum (DE)
- Techniker Krankenkasse (Germany) (DE)
- BARMER GEK (DE)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
- DAK-Gesundheit (Germany) (DE)
- Impact (CA)
- Ludwig-Maximilians-Universität München (DE)
- Otto-von-Guericke-Universität Magdeburg (DE)
- McMaster University (CA)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1186/s13195-025-01902-8
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00